Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · Annals of Oncology · 2014

Cited by 7 works. doi:10.1093/annonc/mdu438.39

Authors